SUBMISSION OF DISCLOSURE UNDER REGULATION 29(2)
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Beryl Drugs Ltd has submitted a disclosure to BSE under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations. This type of filing is typically made when a promoter or major shareholder's encumbered (pledged) shares change, or when there is a change in their voting rights or shareholding in the company. The actual details of the disclosure — including figures, the party involved, and the nature of the change — are not available, as the linked BSE document page returned an error and could not be accessed. Without the underlying data, the specific transaction or change being reported cannot be confirmed.
Investors should look for the detailed disclosure from Beryl Drugs Ltd to understand any changes in promoter shareholding or pledge status, as such disclosures can affect stock price sentiment. Until the full document is reviewed, the material impact on shareholders remains unclear.